Patents by Inventor Jakob Dupont

Jakob Dupont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190284269
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: November 30, 2017
    Publication date: September 19, 2019
    Inventors: Jakob DUPONT, Hema PARMAR
  • Publication number: 20190023776
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly pancreatic, colorectal, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., gemcitabine and ABRAXANE®; leucovorin, 5-fluorouracil, and irinotecan; and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a pancreatic, colorectal, or endometrial tumor. Also described are methods of treating cancer, particularly pancreatic, colorectal, and endometrial cancer, comprising administering a therapeutically effect amount of an agent, antibody, or therapeutic combination of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 24, 2019
    Inventors: Jakob DUPONT, Hema PARMAR, Robert Joseph STAGG
  • Publication number: 20190000970
    Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.
    Type: Application
    Filed: April 25, 2018
    Publication date: January 3, 2019
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Jakob DUPONT, Robert J. STAGG
  • Publication number: 20180344847
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • Publication number: 20180273618
    Abstract: The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.
    Type: Application
    Filed: February 6, 2018
    Publication date: September 27, 2018
    Inventors: Christopher Lamond MURRIEL, Timothy Charles HOEY, Austin L. GURNEY, Julie Michelle RODA, Minu K. SRIVASTAVA, Inkyung PARK, Jakob DUPONT
  • Patent number: 9987357
    Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 5, 2018
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Jakob Dupont, Robert J. Stagg
  • Publication number: 20170299598
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Application
    Filed: February 1, 2017
    Publication date: October 19, 2017
    Inventors: Steven Eugene BENNER, Robert Joseph Stagg, Jakob Dupont
  • Publication number: 20170157245
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly gastric cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit growth of a gastric tumor. Also described are methods of treating gastric cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a gastric tumor or gastric cancer.
    Type: Application
    Filed: April 3, 2015
    Publication date: June 8, 2017
    Inventor: Jakob DUPONT
  • Publication number: 20170143826
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 25, 2017
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • Patent number: 9599620
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 21, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Steven Eugene Benner, Robert Joseph Stagg, Jakob Dupont
  • Publication number: 20170022289
    Abstract: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of an anti-Notch 1 antibody.
    Type: Application
    Filed: March 4, 2015
    Publication date: January 26, 2017
    Applicant: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Jakob Dupont, Ann M. Kapoun, Belinda Cancilla
  • Publication number: 20160346388
    Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.
    Type: Application
    Filed: May 5, 2016
    Publication date: December 1, 2016
    Inventors: Jakob DUPONT, Robert J. Stagg
  • Publication number: 20160334423
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Application
    Filed: March 15, 2016
    Publication date: November 17, 2016
    Inventors: Steven Eugene BENNER, Robert Joseph Stagg, Jakob Dupont
  • Publication number: 20160279241
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: June 16, 2016
    Publication date: September 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • Publication number: 20160235844
    Abstract: Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a Wnt antagonist. In one embodiment, the Wnt antagonist is an anti-FZD antibody. In another embodiment, the Wnt antagonist is a soluble FZD receptor polypeptide. In a further embodiment, the Wnt antagonist is an anti-Wnt antibody.
    Type: Application
    Filed: January 12, 2016
    Publication date: August 18, 2016
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Robert Joseph Stagg, Jakob Dupont
  • Publication number: 20160176962
    Abstract: The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.
    Type: Application
    Filed: October 30, 2015
    Publication date: June 23, 2016
    Inventors: Christopher Lamond Murriel, Timothy Charles Hoey, Austin L. Gurney, Julie Michelle Roda, Minu K. Srivastava, Inkyung Park, Jakob Dupont
  • Patent number: 9359444
    Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: June 7, 2016
    Assignee: OncoMed Pharmaceuticals Inc.
    Inventors: Jakob Dupont, Robert J. Stagg
  • Patent number: 9266959
    Abstract: Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a Wnt antagonist. In one embodiment, the Wnt antagonist is an anti-FZD antibody. In another embodiment, the Wnt antagonist is a soluble FZD receptor polypeptide. In a further embodiment, the Wnt antagonist is an anti-Wnt antibody.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: February 23, 2016
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Robert Joseph Stagg, Jakob Dupont
  • Publication number: 20150232570
    Abstract: NOTCH1-binding antibodies and methods of using the antibodies for treating hematologic cancers are disclosed. Methods of using antibodies that bind to a non-ligand binding membrane proximal region of the extracellular domain of human NOTCH1 and methods of treating chronic lymphocytic leukemia (CLL), hairy cell leukemia, chronic myelogenous leukemia (CML), nonHodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or cutaneous T-cell lymphoma (CTCL) in a subject, comprising administering a therapeutically effective amount of a NOTCH1-binding antibody to the subject are also disclosed. Methods of identifying subjects suitable for such treatment methods are further disclosed.
    Type: Application
    Filed: September 20, 2013
    Publication date: August 20, 2015
    Applicant: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Timothy C. Hoey, Ann M. Kapoun, Min Wang, Tzu-Ling Tang Lin, Jennifer Anne Cain, Jakob Dupont
  • Publication number: 20140242078
    Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.
    Type: Application
    Filed: February 3, 2014
    Publication date: August 28, 2014
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Jakob DUPONT, Robert J. STAGG